# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Abeona Therapeutics' pz-cel gets the FDA's Complete Response Letter and Abeona's plans for fulfilling Chemistry Man...
Cantor Fitzgerald analyst Kristen Kluska reiterates Abeona Therapeutics (NASDAQ:ABEO) with a Overweight and maintains $36 pr...
ABEO: -55% | Abeona Therapeutics shares are trading lower after the company announced the FDA issued a Complete Response Letter...